Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE2.1700
- TODAY'S CHANGE (%)-0.1900 (-8.0508%)
- Bid / Lots2.1700/ 2
- Ask / Lots2.1900/ 1
- Open / Previous Close2.4100 / 2.3600
- Day Range
- 52 Week Range
- Volume83,475
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 3661 | 2.4 |
| 09:34 ET | 300 | 2.3979 |
| 09:36 ET | 1000 | 2.38 |
| 09:38 ET | 2050 | 2.3201 |
| 09:39 ET | 1970 | 2.3078 |
| 09:41 ET | 12578 | 2.29 |
| 09:45 ET | 4897 | 2.24 |
| 09:48 ET | 1887 | 2.25 |
| 09:54 ET | 500 | 2.2633 |
| 09:56 ET | 100 | 2.26 |
| 09:57 ET | 1125 | 2.26 |
| 09:59 ET | 2026 | 2.3012 |
| 10:01 ET | 610 | 2.3 |
| 10:14 ET | 700 | 2.25 |
| 10:17 ET | 1153 | 2.235 |
| 10:19 ET | 3498 | 2.245 |
| 10:21 ET | 666 | 2.2395 |
| 10:24 ET | 500 | 2.2422 |
| 10:28 ET | 177 | 2.2581 |
| 10:32 ET | 800 | 2.2401 |
| 10:33 ET | 100 | 2.245 |
| 10:35 ET | 450 | 2.2493 |
| 10:39 ET | 350 | 2.2403 |
| 10:42 ET | 500 | 2.23 |
| 10:46 ET | 1100 | 2.24 |
| 10:48 ET | 700 | 2.24 |
| 10:51 ET | 500 | 2.24 |
| 10:57 ET | 125 | 2.26 |
| 11:00 ET | 100 | 2.2543 |
| 11:02 ET | 700 | 2.2441 |
| 11:08 ET | 223 | 2.2399 |
| 11:13 ET | 200 | 2.2391 |
| 11:18 ET | 1000 | 2.235 |
| 11:20 ET | 469 | 2.235 |
| 11:38 ET | 175 | 2.2311 |
| 11:40 ET | 1988 | 2.205 |
| 11:42 ET | 1108 | 2.2001 |
| 11:45 ET | 566 | 2.2093 |
| 11:56 ET | 1000 | 2.205 |
| 11:58 ET | 126 | 2.2 |
| 12:00 ET | 259 | 2.2012 |
| 12:07 ET | 500 | 2.2001 |
| 12:12 ET | 620 | 2.2 |
| 12:16 ET | 4631 | 2.19 |
| 12:18 ET | 1214 | 2.1538 |
| 12:20 ET | 3354 | 2.19 |
| 12:27 ET | 294 | 2.185 |
| 12:32 ET | 600 | 2.1809 |
| 12:34 ET | 2300 | 2.195 |
| 12:38 ET | 100 | 2.195 |
| 12:39 ET | 200 | 2.195 |
| 12:41 ET | 100 | 2.192 |
| 12:43 ET | 100 | 2.195 |
| 12:45 ET | 110 | 2.19 |
| 12:52 ET | 600 | 2.1915 |
| 01:10 ET | 1100 | 2.185 |
| 01:15 ET | 500 | 2.1806 |
| 01:26 ET | 100 | 2.181 |
| 01:33 ET | 126 | 2.1818 |
| 01:35 ET | 1871 | 2.185 |
| 01:37 ET | 1600 | 2.1899 |
| 01:42 ET | 365 | 2.1892 |
| 01:57 ET | 100 | 2.1801 |
| 02:00 ET | 300 | 2.1794 |
| 02:04 ET | 750 | 2.1764 |
| 02:11 ET | 500 | 2.175 |
| 02:13 ET | 3399 | 2.17 |
Today
Jul 1, 2024
DJ Immix Biopharma Initiated at Buy by HC Wainwright & Co., from 6:20AM ET on Monday Jul 01, 2024 by Dow Jones
6:20AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 17, 2024
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum, from 9:35AM ET on Monday Jun 17, 2024 by Dow Jones
9:35AM ET on Monday Jun 17, 2024 by Dow JonesImmix Biopharma to Present at the Stifel 2024 Cell Therapy Forum, from 9:35AM ET on Monday Jun 17, 2024 by Dow Jones
9:35AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 62.3M | -2.3x | --- |
RetinalGenix Technologies Inc | 62.5M | -16.5x | --- |
Vor Biopharma Inc | 62.0M | -0.5x | --- |
Aileron Therapeutics Inc | 62.0M | -1.0x | --- |
Bioatla Inc | 63.5M | -0.5x | --- |
Genenta Science SPA | 56.4M | -4.7x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 26.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.93 |
Book Value | $0.82 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
